Angiolab, Inc. signed a contract to acquire NH Special Purpose Acquisition 13 Co., Ltd. from BNK Venture Investment and others in a reverse merger transaction for KRW 66.3 billion.

Angiolab, Inc. (XKON:A251280) signed a contract to acquire NH Special Purpose Acquisition 13 Co., Ltd. (KOSDAQ:A310840) from BNK Venture Investment and others in a reverse merger transaction for KRW 66.3 billion on June 29, 2020. merger ratio is NH Special Purpose Acquisition 13 Co., Ltd. : Angio Lab = 1: 7.6000000. When the merger of NH Special Purpose Acquisition 13 Co., Ltd. and AngioLab is completed, formally NH Special Purpose Acquisition 13 Co., Ltd. becomes a surviving corporation, and AngioLab becomes an extinction corporation.

However, practically, AngioLab will be listed on the KOSDAQ market while maintaining business continuity. Shareholders meeting is scheduled for October 21, 2020. The deal is resolved by board on June 29, 2020.

Date of merger is November 24, 2020. Scheduled merger registration date is November 26, 2020. Jeongin Accounting Corporation acted as evaluator for Angiolab, Inc.